secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001404644-25-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene posts FY2024 net loss $75.1M, cash $312.4M, NGN-401 gets EMA PRIME, trial updates
--------------------------------------------------------------------------------

- Cash and marketable securities $312.4M as of Dec 31, 2024; runway into H2 2027 to support NGN-401 registrational trial and pipeline.
- R&D expenses $60.9M in FY2024 (up from $44.4M) on higher Rett trial costs and headcount; net loss $75.1M vs $36.3M prior year.
- NGN-401 Phase 1/2 trial: dose fixed at 1E15 vg, age range expanded >11 years; received EMA PRIME designation.
- Anticipated milestones: regulatory update on registrational plans in H1 2025; additional interim clinical data in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/0001404644-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/ngne-20250324.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer